Physics:Deudomperidone
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | CIN-102; deuterated domperidone; domperidone deuterated |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H20ClD4N5O2 |
| Molar mass | 429.94 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Deudomperidone (developmental code name CIN-102; also known as deuterated domperidone) is a dopamine antagonist medication which is under development in the United States for the treatment of gastroparesis.[1][2][3] It acts as a selective dopamine D2 and D3 receptor antagonist and has peripheral selectivity.[2][3] Deudomperidone is a deuterated form of domperidone, and it is suggested that deudomperidone may have improved efficacy, tolerability, and pharmacokinetics compared to domperidone.[2][3] As of January 2022, deudomperidone is in phase 2 clinical trials for the treatment of gastroparesis.[1]
See also
References
- ↑ 1.0 1.1 "Deudomperidone - CinRx Pharma". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800050807.
- ↑ 2.0 2.1 2.2 "Nausea and Vomiting in 2021: A Comprehensive Update". Journal of Clinical Gastroenterology 55 (4): 279–299. April 2021. doi:10.1097/MCG.0000000000001485. PMID 33471485.
- ↑ 3.0 3.1 3.2 "Antiemetic therapy for gastroparesis". Gastroparesis. Elsevier. 2021. pp. 341–359. doi:10.1016/B978-0-12-818586-5.00025-9. ISBN 9780128185865.
External links
 |  |
